TK1: A Protein Target for Drug Development (G7083)

Target Name: TK1

NCBI ID: G7083

Content of Review Report on TK1 Target / Biomarker

TK1

TK1: A Protein Target for Drug Development

TK1 (Thymidine kinase 1) is a protein that is expressed in most tissues of the body. It plays a crucial role in the regulation of DNA replication, cell growth, and apoptosis. TK1 has also been implicated in the development and progression of many diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. As a result, TK1 has become an attractive drug target for researchers to explore for new treatments.

The TK1 enzyme is involved in the regulation of DNA replication, which is a critical process for the growth and development of most organisms. During DNA replication, TK1 helps to ensure that the two copies of the DNA are accurately duplicated and that any errors or mutations are corrected. TK1 is also involved in the regulation of cell growth, which is critical for the development and progression of cancer.

In addition to its role in DNA replication and cell growth, TK1 has also been implicated in the regulation of apoptosis, which is the process by which cells die when they have reached a certain level of dysfunction or when they are no longer needed. TK1 has been shown to play a role in the regulation of apoptosis in many different cell types, including cancer cells.

TK1 has also been linked to the development and progression of many neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. These disorders are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the symptoms of these disorders. TK1 has been shown to play a role in the regulation of neurofibrillary tangles and the loss of brain cells, which may contribute to the development and progression of these disorders.

In addition to its role in the regulation of DNA replication, cell growth, and apoptosis, TK1 has also been implicated in the development and progression of many autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. These disorders are characterized by the immune system attacking the body's own tissues, which can lead to inflammation, pain, and other symptoms. TK1 has been shown to play a role in the regulation of immune system function, which may contribute to the development and progression of these autoimmune diseases.

Given the involvement of TK1 in so many different processes in the body, it is not surprising that it has become an attractive drug target for researchers. Many researchers are working to develop drugs that can inhibit TK1 activity and treat a wide range of diseases. These drugs can include small molecules, such as inhibitors of TK1 kinase activity, as well as antibodies that target TK1 directly.

In addition to its potential as a drug target, TK1 is also a potential biomarker for many different diseases. The levels of TK1 in cells can be easily measured, which allows researchers to monitor the effectiveness of drugs and other treatments. This can be an important tool for the development of new treatments for a wide range of diseases.

Overall, TK1 is a protein that plays a crucial role in the regulation of DNA replication, cell growth, and apoptosis. It has also been implicated in the development and progression of many diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. As a result, TK1 has become an attractive drug target for researchers to explore for new treatments.

Protein Name: Thymidine Kinase 1

Functions: Cell-cycle-regulated enzyme of importance in nucleotide metabolism (PubMed:9575153). Catalyzes the first enzymatic step in the salvage pathway converting thymidine into thymidine monophosphate (PubMed:22385435). Transcriptional regulation limits expression to the S phase of the cell cycle and transient expression coincides with the oscillation in the intracellular dTTP concentration (Probable). Also important for the activation of anticancer and antiviral nucleoside analog prodrugs such as 1-b-d-arabinofuranosylcytosine (AraC) and 3c-azido-3c-deoxythymidine (AZT) (PubMed:22385435)

The "TK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets